• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Artelo Biosciences Announces Presentation of Positive Interim Phase 2 CAReS Data on ART27.13 at the 2025 Cancer Cachexia Society Conference

    9/29/25 8:30:00 AM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARTL alert in real time by email

    Patients treated with ART27.13 showed consistent improvements in weight, lean body mass, and activity

    While clinical benefits were observed in all treated cohorts, the best outcomes in CAReS were observed in patients titrated to the highest dose

    SOLANA BEACH, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced the first public presentation of the interim data from its Phase 2 Cancer Appetite Recovery Study (CAReS) evaluating ART27.13 in patients with cancer anorexia-cachexia syndrome (CACS). The data were presented by Barry Laird, Professor of Palliative Medicine, Oslo University Hospital - Radium Hospital and University of Oslo, Norway, and Chief Investigator in CAReS, at the 8th Cancer Cachexia Society (CCS) Conference held September 25–27, 2025 in Turin, Italy.

    The CCS presentation showed the actual interim data underlying previously announced summary results of ART27.13's potential to meaningfully impact weight gain, lean body mass, and daily activity in patients with CACS. Importantly, Professor Laird's presentation introduced new insights from digital wearable data, which showed that patients treated with ART27.13 had greater frequency and intensity in daily activity compared to placebo, reinforcing the therapy's potential to improve both physical outcomes and quality of life in cancer patients suffering from this debilitating condition.

    Interim Data Highlights

    • Weight Gain: Patients who had lost at least 5% of body weight to be included in CAReS and titrated to the highest ART27.13 dose (1300 µg) achieved an average +6% weight gain over 12 weeks, while patients on placebo lost an additional ~5%.
    • Lean Body Mass: Improvements in lean body mass were aligned with total weight gains, suggesting preservation or accrual of muscle, consistent with pre-clinical research with ART27.13.
    • Activity: Digital wearable data confirmed greater daily activity metrics among treated patients compared to placebo.
    • Safety: ART27.13 continued to exhibit a favorable safety profile, with adverse events mostly mild to moderate and no serious drug-related events reported.

    Steven D. Reich, MD, Chief Medical Officer at Artelo commented, "These interim findings provide strong evidence that ART27.13 can help address the profound weight and activity loss experienced by patients with cancer anorexia-cachexia syndrome. With ART27.13 we are seeing consistent improvements not just in weight, but also in lean body mass and activity—outcomes that are highly meaningful to patients' daily lives."

    In addition to CCS participants hearing Professor Laird's presentation, Artelo's Senior Vice President and Chief Scientific Officer, Andy Yates, PhD, attended CCS 2025 to engage with global thought leaders and advance partnering discussions with pharmaceutical companies that have expressed interest in ART27.13. These efforts are aligned with the Company's strategy to maximize the therapeutic and commercial potential of its lead program.

    "Discussing the interim CAReS results at CCS 2025 allowed us to engage with the global research community, foster collaboration, and advance partnering discussions for a much-needed therapy in this area of critical unmet need," added Dr. Yates.

    Data from Professor Laird's presentation have been added to Artelo's corporate presentation available on the Company's website here.

    About ART27.13

    ART27.13 is a novel benzimidazole derivative and dual cannabinoid agonist being developed as a once-daily, orally administered agent selectively targeting peripheral CB1 and CB2 receptors, with the potential to improve body weight, appetite, muscle degeneration, and quality of life in cancer patients. Initially developed by AstraZeneca plc, ART27.13 has been in seven clinical studies with over 280 participants. A statistically significant and dose-dependent increase in body weight was observed in people with back pain who were otherwise healthy. Importantly, the drug enables systemic metabolic effects while minimizing central nervous system-mediated toxicity. Having completed the Phase 1 portion of the CAReS study in cancer patients where ART27.13 demonstrated an excellent safety profile, Artelo is conducting the Phase 2 portion of the trial as a supportive care therapy for cancer patients suffering from anorexia and weight loss. Currently, there is no FDA approved treatment for cancer anorexia cachexia syndrome.

    About CAReS

    The Cancer Appetite Recovery Study (CAReS) is a Phase 1/2 randomized, placebo-controlled trial of the Company's lead clinical program, ART27.13, in patients with cancer anorexia and weight loss. Cancer-related anorexia, or the lack or loss of appetite in the person with cancer, may result from the cancer and/or its treatment with radiation or chemotherapy. It is common for people with cancer to lose weight. Anorexia and the resulting weight loss can affect a patient's health, often weakening their immune system and causing discomfort and dehydration. A weight loss of more than 5% can predict a poor outcome for cancer patients and a lower response to chemotherapy. The Phase 1 portion of the CAReS study was designed to determine the most effective and safest initial dose of ART27.13 in the Phase 2 stage. The Phase 2 stage of the CAReS study is designed to determine estimates of activity of ART27.13 in terms of lean body mass, weight gain, and improvement of anorexia compared to placebo.

    (ISRCTN registry: https://www.isrctn.com/ISRCTN15607817)

    About CACS

    Cancer Anorexia-Cachexia Syndrome (CACS) is a condition marked by loss of appetite, weight loss, and the breakdown of muscle and fat, affecting up to 80% of patients with advanced cancer- representing a greater than $3 billion addressable market. This loss of appetite, known as anorexia, may result from the cancer itself or from treatments such as radiation and chemotherapy. The resulting weight loss can weaken the immune system, cause discomfort and dehydration, and lower a patient's ability to tolerate treatment. Losing more than 5% of body weight is associated with poorer outcomes and reduced response to chemotherapy. While drugs that stimulate appetite have been used off-label to help manage cancer-related anorexia, there are currently no approved treatments in the US, UK, or EU for this condition.

    About Artelo Biosciences

    Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways, with a diversified pipeline addressing significant unmet needs in anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Led by an experienced executive team collaborating with world-class researchers and digital-asset technology partners, Artelo applies rigorous scientific, regulatory, commercial, and treasury management practices, including digital assets, to maximize stakeholder value. More information is available at www.artelobio.com and X: @ArteloBio.

    Forward Looking Statements

    This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product candidate development strategies, clinical and regulatory timelines or results, market opportunity, competitive positions, possible or assumed future results of operations or research, business strategies, potential growth opportunities, treasury strategies, and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws.

    Investor Relations Contact:

    Crescendo Communications, LLC

    Tel: 212-671-1020

    Email: [email protected]



    Primary Logo

    Get the next $ARTL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARTL

    DatePrice TargetRatingAnalyst
    7/8/2025$20.00Hold → Buy
    D. Boral Capital
    11/1/2021$4.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $ARTL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Artelo Biosciences Announces Expanded Clinical Data to be Presented on both ART26.12 and ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit

    ART26.12 Phase 1 Data Demonstrated No Safety Concerns, Predictable Linear Plasma Exposure, and Options for Dosing in Either Fed or Fasted Conditions  ART27.13 Interim Phase 2 Data Showed Substantial Weight Gain and Activity Improvements in the Treated Patients versus Placebo SOLANA BEACH, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced that Professor Saoirse O'Sullivan, Vice President of Translational Sciences at Artelo Biosciences, is presenting expand

    10/15/25 9:15:00 AM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Artelo Biosciences Announces Closing of $2.0 Million Public Offering

    SOLANA BEACH, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced the closing of its previously announced underwritten public offering of 441,210 shares of its common stock at a price to the public of $4.40 per share and pre-funded warrants to purchase up to 13,335 shares of Artelo's common stock at a price to the public of $4.399 per pre-funded warrant, which represents the per share public offering price of each share of Artelo's common stock less the $0.00

    10/1/25 4:05:00 PM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Artelo Biosciences Announces Pricing of $2.0 Million Public Offering

    SOLANA BEACH, Calif., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced the pricing of its previously announced underwritten public offering of 441,210 shares of its common stock at a price to the public of $4.40 per share and pre-funded warrants to purchase up to 13,335 shares of Artelo's common stock at a price to the public of $4.399 per pre-funded warrant, which represents the per share public offering price of each share of Artelo's common stock less the $0.0

    9/30/25 8:30:00 AM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARTL
    SEC Filings

    View All

    Artelo Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)

    10/17/25 4:30:34 PM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Artelo Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)

    10/1/25 5:28:39 PM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Artelo Biosciences Inc.

    424B5 - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)

    10/1/25 11:06:45 AM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARTL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by President, CEO, CFO, Treasurer Gorgas Gregory D.

    4 - ARTELO BIOSCIENCES, INC. (0001621221) (Issuer)

    7/7/25 4:40:52 PM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Favorito Tamara A

    4 - ARTELO BIOSCIENCES, INC. (0001621221) (Issuer)

    5/5/25 5:24:07 PM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Matsui Connie

    4 - ARTELO BIOSCIENCES, INC. (0001621221) (Issuer)

    5/5/25 5:21:52 PM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARTL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Artelo Biosciences upgraded by D. Boral Capital with a new price target

    D. Boral Capital upgraded Artelo Biosciences from Hold to Buy and set a new price target of $20.00

    7/8/25 8:21:40 AM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. initiated coverage on Artelo Biosciences with a new price target

    HC Wainwright & Co. initiated coverage of Artelo Biosciences with a rating of Buy and set a new price target of $4.00

    11/1/21 6:29:39 AM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LADENBURG THALM/SH SH initiated coverage on Artelo Biosciences

    LADENBURG THALM/SH SH initiated coverage of Artelo Biosciences with a rating of Buy

    2/12/21 7:33:23 AM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARTL
    Leadership Updates

    Live Leadership Updates

    View All

    Kintara Therapeutics Appoints Tamara A. Seymour to Board of Directors

    SAN DIEGO, May 4, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced the appointment of Tamara A. Seymour to the Company's Board of Directors replacing John Liatos, who will continue in his role as Kintara's Senior Vice President of Business Development. "We are delighted to welcome Tamara to the Board of Directors as she brings exceptional healthcare sector experience as an accomplished financial and operational executive," comm

    5/4/21 8:00:00 AM ET
    $KTRA
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Artelo Biosciences Appoints Finance and Healthcare Industry Executive Tamara A. Seymour to Board of Directors

    LA JOLLA, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system, today announced the appointment of Tamara A. Seymour, CPA, to the Company’s board of directors. “We are pleased to welcome Tamara to Artelo’s board of directors,” said Connie Matsui, Board Chair. “Tamara brings with her an impressive track record in corporate finance and capital markets, as well as extensive experience guiding biopharmaceutical and diagnostic companies from clinical stage to commercialization. We believe her advice a

    3/9/21 8:30:00 AM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Artelo Biosciences Announces Appointment of Andrew Yates, Ph.D. as Senior Vice President and Chief Scientific Officer

    LA JOLLA, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced the appointment of Andrew Yates, Ph.D, as Senior Vice President and Chief Scientific Officer. Dr. Yates is an experienced senior pharmaceutical executive, having served most recently at AstraZeneca, in significant roles across a number of functional areas including development and commercial strategy, medical affairs, and business development. Notably, Dr. Yates has been extensively involved in the life-cycle managem

    2/16/21 8:30:00 AM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARTL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Artelo Biosciences Inc. (Amendment)

    SC 13G/A - ARTELO BIOSCIENCES, INC. (0001621221) (Subject)

    2/23/22 4:36:39 PM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Artelo Biosciences Inc. (Amendment)

    SC 13G/A - ARTELO BIOSCIENCES, INC. (0001621221) (Subject)

    2/9/22 11:08:31 AM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Artelo Biosciences Inc. (Amendment)

    SC 13G/A - ARTELO BIOSCIENCES, INC. (0001621221) (Subject)

    2/4/22 3:19:12 PM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care